Waldencast PLC

WALD is in a Stage 2 advancing regime with higher highs and higher lows above rising EMAs and the 50SMA, underpinning a bullish medium-term bias. The recent pullback into the 9/21 EMA is healthy and offers a constructive entry with neutral OB/OS context and no exhaustion. However, the longer-term trend remains down, and stage transition risk into distribution at the May highs underscores the need for caution. We will engage on this pullback into EMAs support.

• ↑FDA approved Obagi saypha ChIQ gel; 94% of injectors view it as complementary, driving dermal filler expansion.
• ↑Divested Obagi Medical for up to $460M, earmarked for debt reduction and Milk Makeup growth.
• ↓Profitability is weak, indicating struggles to generate sustainable returns.